Lincoln National Corp Regeneron Pharmaceuticals, Inc. Transaction History

Lincoln National Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$902.69 - $993.35 $92,977 - $102,315	-103 Reduced 13.36%	668 $642,000
Q4 2023 Feb 06, 2024	BUY	$775.18 - $881.7 $198,446 - $225,715	256 Added 49.71%	771 $677,000
Q3 2023 Nov 03, 2023	BUY	$692.45 - $844.37 $7,616 - $9,288	11 Added 2.18%	515 $423,000
Q2 2023 Aug 04, 2023	BUY	$700.03 - $830.35 $63,002 - $74,731	90 Added 21.74%	504 $362,000
Q1 2023 May 01, 2023	BUY	$680.49 - $826.97 $25,858 - $31,424	38 Added 10.11%	414 $340,000
Q4 2022 Feb 07, 2023	BUY	$705.89 - $766.39 $265,414 - $288,162	376 New	376 $271,000
Q1 2020 Apr 24, 2020	SELL	$336.18 - $494.43 $218,853 - $321,873	-651 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$274.13 - $376.51 $178,458 - $245,108	651 New	651 $245,000

1,463

84.5M

907K

1.3M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $109B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.